Butterfly Network (BFLY) Stock Surges 22% Following Bullish Analyst Coverage

Key Points

• BFLY shares surged 22% on Tuesday, closing at $9.93.
• Needham initiated coverage with a Buy recommendation and $10 price objective.
• Analysts emphasized the company’s semiconductor-based ultrasound platform and Embedded division.
• The company announced record quarterly sales of $32.6 million in its latest report.
• Shares traded near $10 during Wednesday’s premarket session.

Butterfly Network (BFLY) shares experienced a significant 22% surge on Tuesday following Needham’s initiation of coverage with a Buy recommendation and a $10 price objective. The stock closed at $9.93, marking a substantial increase from the prior session’s $8.14.

Butterfly Network, Inc., BFLY

The momentum extended into Wednesday morning’s premarket trading, though at a more moderate pace. BFLY shares hovered around $9.98, representing approximately a 0.5% gain, after touching $10.05 earlier in the session.

Needham’s analyst David Saxon emphasized Butterfly’s proprietary cMUT semiconductor-based ultrasound platform as a cornerstone of his optimistic outlook. According to the firm, this innovative technology could enable medical applications extending well beyond the company’s established handheld ultrasound devices.

Analyst Highlights Expansion Opportunities Beyond Traditional Markets

The Needham report drew particular attention to Butterfly Embedded, a division enabling third-party manufacturers to incorporate Butterfly’s ultrasound-on-chip technology into their own products. Saxon views this business segment as a strategic pathway for Butterfly to penetrate additional medical sectors without bearing the full burden of product development.

The analyst further noted that Butterfly’s core ultrasound platform presents additional upside potential. According to Needham’s assessment, several forthcoming products and applications in the pipeline could serve as near-term growth catalysts.

Investor focus has increasingly centered on Butterfly’s collaborative partnership approach. The company recently finalized a multi-year licensing deal with Merge Labs, granting access to its ultrasound technology for the creation of minimally invasive brain-computer interface solutions.

Additionally, Butterfly collaborates with Midjourney Medical, which is engineering a comprehensive full-body ultrasound imaging platform utilizing Butterfly’s proprietary technology. Needham considers these Embedded partnerships integral to the overall investment thesis.

Needham’s $10 target now sits marginally above Tuesday’s $9.93 close. According to FactSet data referenced by MT Newswires, the consensus analyst price target stands at approximately $10.50.

Strong Financial Results Bolster Investor Confidence

Butterfly’s latest financial metrics provide additional support for the stock’s rally. The company disclosed second-quarter revenue of $32.6 million, representing 39% year-over-year growth from the prior year’s $23.4 million.

This distinction matters because certain reports inaccurately cited $15.72 million as the quarter’s total revenue. In reality, $15.72 million represented product revenue exclusively, while software and additional services generated another $16.89 million.

Gross margin expanded to 71.4% compared to 63.7% in the year-ago period, benefiting from higher-margin Embedded licensing revenues. The company also reduced its adjusted EBITDA loss to $1.4 million from $6.2 million previously.

Management upgraded its 2026 revenue guidance to a range of $119 million to $123 million while projecting an adjusted EBITDA loss between $19 million and $23 million. As of the end of June, Butterfly maintained $124.7 million in cash and cash equivalents.

Primary concerns include valuation metrics, ongoing operational losses, and uncertainty surrounding whether emerging Embedded products will achieve meaningful commercial traction. Needham’s report also acknowledged competitive pressure from established medical-imaging corporations and the likelihood that Butterfly will require substantial ongoing investment to advance future technology iterations.

Currently, Needham’s fresh Buy recommendation appears to have been the catalyst behind Tuesday’s impressive 22% advance. Early Wednesday trading indicates BFLY maintaining its position near $10 following this notable single-session gain.